Cargando…

COVID-19 in multiple sclerosis patients treated with dimethyl fumarate

Detalles Bibliográficos
Autores principales:	Capone, Fioravante, Ferraro, Elisabetta, Motolese, Francesco, Di Lazzaro, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Letter to the Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896828/ https://www.ncbi.nlm.nih.gov/pubmed/33611610 http://dx.doi.org/10.1007/s00415-021-10446-4

Ejemplares similares

COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review
por: Capone, Fioravante, et al.
Publicado: (2021)

COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis
por: Mantero, Vittorio, et al.
Publicado: (2020)

The Psychological Impact of COVID-19 Pandemic on People With Multiple Sclerosis
por: Motolese, Francesco, et al.
Publicado: (2020)

Safety, immunogenicity, efficacy, and acceptability of COVID-19 vaccination in people with multiple sclerosis: a narrative review
por: Capone, Fioravante, et al.
Publicado: (2022)

The Potential Role of Neurophysiology in the Management of Multiple Sclerosis-Related Fatigue
por: Capone, Fioravante, et al.
Publicado: (2020)

Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies
por: Capone, Fioravante, et al.
Publicado: (2021)

Ischemic Stroke in a Patient with Stable CADASIL during COVID-19: A Case Report
por: Cruciani, Alessandro, et al.
Publicado: (2021)

CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient
por: Kogel, Ann-Kathrin, et al.
Publicado: (2021)

Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review
por: Capone, Fioravante, et al.
Publicado: (2022)

Extremely Low Frequency Magnetic Fields Do Not Affect LTP-Like Plasticity in Healthy Humans
por: Capone, Fioravante, et al.
Publicado: (2020)

Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate
por: Bollo, Luca, et al.
Publicado: (2022)

Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate
por: Baharnoori, Moogeh, et al.
Publicado: (2016)

Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome in patients with COVID-19 infection: is there a link? A systematic review and case report analysis
por: Bonura, Adriano, et al.
Publicado: (2023)

Transcranial direct current stimulation in semantic variant of primary progressive aphasia: a state-of-the-art review
por: Norata, Davide, et al.
Publicado: (2023)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
por: Jaber, Aliya, et al.
Publicado: (2023)

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
por: Spencer, Collin M., et al.
Publicado: (2015)

Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate
por: Ma, Brandy B., et al.
Publicado: (2016)

Lymphocyte subtypes in relapsing–remitting multiple sclerosis patients treated with dimethyl fumarate
por: Chaves, C, et al.
Publicado: (2017)

Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
por: Lyons, Jennifer, et al.
Publicado: (2022)

Parkinson's Disease Remote Patient Monitoring During the COVID-19 Lockdown
por: Motolese, Francesco, et al.
Publicado: (2020)

Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021)

Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study
por: Comi, Giancarlo, et al.
Publicado: (2023)

A smart devices based secondary prevention program for cerebrovascular disease patients
por: Motolese, Francesco, et al.
Publicado: (2023)

Effects Mediated by Dimethyl Fumarate on In Vitro Oligodendrocytes: Implications in Multiple Sclerosis
por: Guerriero, Claudia, et al.
Publicado: (2022)

Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
por: Sangurdekar, Dipen, et al.
Publicado: (2019)

CORRIGENDUM to Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
Publicado: (2023)

Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2021)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study
por: Marastoni, Damiano, et al.
Publicado: (2019)

Posterior Reversible Encephalopathy Syndrome and brain haemorrhage as COVID-19 complication: a review of the available literature
por: Motolese, Francesco, et al.
Publicado: (2021)

Thyroid Disorders in Patients Treated with Dimethyl Fumarate for Multiple Sclerosis: A Retrospective Observational Study
por: Renaud, Cédric O., et al.
Publicado: (2022)

Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate
por: Sánchez-Sanz, Alicia, et al.
Publicado: (2022)

Smartphone App in Stroke Management: A Narrative Updated Review
por: Bonura, Adriano, et al.
Publicado: (2022)

Smartphone App in Stroke Management: A Narrative Updated Review
por: Bonura, Adriano, et al.
Publicado: (2023)

The role of neurophysiological tools in the evaluation of ischemic stroke evolution: a narrative review
por: Motolese, Francesco, et al.
Publicado: (2023)

The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
por: Mills, Elizabeth A., et al.
Publicado: (2018)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5s9q6033n5h9fd4ekgi1bghqms